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PRELIMINARY AND SHORT REPORT
TOPICAL APPLICATION OF A NEW DERIVATIVE OF TRIAMGINOLONE IN THE
TREATMENT OF SKIN DISEASES*
F. W. GROwE, M.D., T. B. FITZPATRICK, M.D., S. A. WALKER, M.D. AND ROBERT OLSON, B.A.
Perhaps the most effective anti-inflammatory
compounds in cutaneous medicine are the adrenal
cortical hormones (Jailer, ci al.) (1). Ten years of
experience have constantly expanded the clinical
usefulness of these drugs. Paralleling this, many
serious side effects have been recognized. Fortu-
nately, with topical application, such effects as
peptic ulcer, negative nitrogen balance, osteoporo-
sis, psychosis and moon facies have not yet been
reported. Sodium retention and edema (Fitz-
patrick, ci al. (2); Livingood, ci el.) (3) was noted,
however, following the topical application of
fludrocortisone acetate. Although the anti-in-
flammatory potency of 9-alpha-fluorohydrocorti-
sone (fludrocortisone acetate) was 12 times that of
hydrocortisone, the heightened possibility of
sodium retention has limited it to topical use to
small areas and for limited periods.
In an effort to realize this anti-inflammatory
effect without sodium retention and edema, a
new group of steroidal anti-inflammatory agents
has recently been developed (Fried ci al.) (4).
One of the most potent members of this group, 9-
alpha-fluoro-16-alpha, 17-alpha-isopropylidene di -
oxy-delta-1 ,4-pregnadiene-1 1-beta, 21-diol-3 ,20 di-
one (which has the generic name of triameinolone
acetonidet and referred to in this paper henceforth
as TA), was shown to possess 40 times the anti-in-
flammatory activity of hydrocortisone in the
adrenalectomized rat.
Double-blind studies were undertaken to
demonstrate the clinical usefulness of this prep-
aration. Instead of a placebo control ordinarily
used in this type of study, the manufacturer fur-
nished the investigators with 1% hydrocortisone
lotion (referred to as HG), cream and ointment.
The hydrocortisone preparation was identical in
appearance and consistency with a preparation
containing 0.1% concentration of the TA. Neither
the patient nor the investigator knew the identity
of the preparations used until completion of the
study. By providing an active agent as a control,
patient cooperation was assured. Generally the
placebo is soon recognized by the patient and
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then only the active agent is applied. A striking
comparison of the increased efficacy of the newer
preparation is provided by this means.
Although the medication was provided in lotion,
cream and ointment forms, patient acceptance
was much better with the lotion and cream. The
results with the lotion were more dramatic.
The results clearly define a greater anti-inflam-
matory effect when the TA is used. The subjective
and objective changes on the side on which TA
was applied have occurred in enough patients so
that the sign test indicates significant differences
between TA and HC which favor TA over HC at
better than the 99% confidence level.
A large number of patients (45%) could not
detect any difference between TA and HG. Many
of these patients bad been using various hydro-
cortisone preparations previously and yet noted
a new response to this same agent (HG) used
simultaneously with the TA. This would indicate
a "distant effect" of TA previously described by
many investigators in paired comparison studies
of various topical agents. Another explanation for
the large number of "ties" or equal responses to
TABLE I
Topical iriamcinoione acetonide (TA) compared
with hydrocortisone (HG), paired
comparison method
Acute and chronic
contact dermatitis.
Eczematous derma-
titis
Nummular eczema...
Atopic dermatitis
(Neurodermatitis)..
Psoriasis
Seborrheic dermatitis.
Miscellaneous
Total
* 0.1% triamcinolone acetonide in lotion or
water-washable base.
t 1.0% bydrocortisone in lotion or water-
washable base.
Diagnosis No.Cases
32
17
16
43
2
6
4
120
TA"
over
JICt
17
8
9
20
2
3
2
61
TIC
over
TA
1
0
1
3
0
0
0
5
Rqoally
Effec-
tive
14
9
6
20
0
3
2
54
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both TA and IIC is a possible systemic effect re-
sulting from percutaneous absorption of TA.
There is presumptive but not conclusive evidence
that topical hydrocortisone is absorbed percuta-
neously (Malkinson) (5). A study of two patients
applying 30 mg. of TA daily for seven days in a
lotion form failed to demonstrate sodium retention
or edema. Although further clinical trial may be
necessary to more firmly establish the absence of
sodium retention with topical application, the fact
that oral administration does not result in sodium
retention already bespeaks this advantage for tn-
amcinolone acetonide.
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